Centessa Pharmaceuticals (CNTA) Interest Expenses (2022 - 2026)

Centessa Pharmaceuticals (CNTA) has 5 years of Interest Expenses data on file, last reported at $2.7 million in Q1 2026.

• Interest Expenses for Q1 2026 came in at $2.7 million, down 5.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.3 million (up 8.38% YoY), and the FY2025 annual result was $11.5 million, up 13.57% from the prior year.
• Interest Expenses declined to $2.7 million in Q1 2026 per CNTA's latest filing, from $2.8 million in the prior quarter.
• Over five years, Interest Expenses peaked at $2.9 million in Q3 2025 and troughed at $1.5 million in Q1 2022.
• A 5-year average of $2.4 million and a median of $2.5 million in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2023 and 2026: Interest Expenses surged 56.33% in 2023, then dropped 5.07% in 2026.
• A 5-year view of Interest Expenses shows it stood at $2.2 million in 2022, then rose by 16.66% to $2.6 million in 2023, then declined by 3.54% to $2.5 million in 2024, then grew by 13.27% to $2.8 million in 2025, then slipped by 2.74% to $2.7 million in 2026.
• Business Quant data shows CNTA's Interest Expenses at $2.7 million in Q1 2026, $2.8 million in Q4 2025, and $2.9 million in Q3 2025.